Publication Category: Medications
GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea
-
O'Donnell C, Ryan O, Hogan AE, Killick D, Crilly S, Dodd JD, Murphy DJ, Ryan S, O'Shea D.
GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea Obesity (Silver Spring)
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting
-
Alabduljabbar K, Alsaqaaby M, Neff KJ, Crotty M, le Roux CW.
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting Endocrine
New therapies for obesity
-
Papamargaritis D, le Roux CW, Holst JJ, Davies MJ.
New therapies for obesity Cardiovasc Res
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy
-
de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L, Hemmingway A, Ahmad NN, Bunck MC, Stefanski A.
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy Hypertension
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
-
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
- Nicholls SJ, Tofé S, le Roux CW, D'Alessio DA, Wiese RJ, Pavo I, Brown K, Weerakkody GJ, Zeytinoglu M, Romera IC. Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program Cardiovasc Diabetol
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)
- Al-Ozairi E, Narula K, Miras AD, Taghadom E, Samad AE, Al Kandari J, Alyosef A, Mashankar A, Al-Najim W, le Roux CW. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial) Trials